The amino groups of purified least acidic xylanase (LAX) isomer and carboxyl groups of purified highly acidic xylanase (HAX) isomer from Scopulariopsis sp. were chemically modified, resulting in charge neutralization and reversal. Modification of the second amino group was accompanied by the complete loss of enzyme activity in both the absence and presence of xylose. Multiple alignments of family 10 and 11 xylanases revealed that there is a pair of fully conserved Lys residues only in family 10 members. Xylanase structures from family 10 members showed that one of the conserved Lys residues is found near the active-site cleft that makes an H-bond with the substrate. The LAX and HAX isoenzymes in which one amino and three to four carboxyl groups were modified were subjected to kinetic and thermodynamic characterization. There were no differences in pH optima between the native and modified HAX, but there was a broadening of pH optimum toward the alkaline range for charge-neutralized LAX and a double pH optimum for charge-reversed LAX. TheV max/K m of both modified LAX and HAX decreased relative to the native species. The thermodynamics of xylan hydrolysis showed that the decrease in the catalytic activity of modified LAX enzymes was entropically driven. When compared with native enzyme, the thermostabilities of modified LAX enzymes increased in the presence and decreased in the absence of substrate. The thermodynamics of kinetic stability for modified LAX enzymes revealed that this increase in thermolability was owing to the decrease in DeltaH# with a concomitant increase in DeltaS# compared with native LAX. The thermostabilities of all the modified HAX species decreased except that of charge-neutralized HAX, whose half-life significantly increased in 50% (v/v) aqueous dioxan. These results suggest that the altered properties of the modified enzymes were a result of the conformational changes brought about by chemical modification.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF02729068 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons.
N Engl J Med
November 2024
From the Hope Clinic of the Emory University School of Medicine, Decatur (C.F.K.), and Grady Health System (C.F.K.), and the Division of Infectious Diseases, Emory University-Ponce de Leon Center Clinical Research Site, HIV/AIDS Clinical Trials Unit (V.D.C.), Atlanta - all in Georgia; the Divisions of Pediatric and Adult Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore (A.L.A.); Be Well Medical Center, Berkley, MI (P.B.); the Department of Medicine, University of California, San Diego, San Diego (J.B.), the Department of Medicine, University of California, Los Angeles (J.C.), Ruane Clinical Research (P.J.R.), and Drew Center for AIDS Research, Education, and Services, Charles R. Drew University (L.Y.S.), Los Angeles, Optimus Medical Group/StudyOps, San Francisco (S.H.), Mills Clinical Research, West Hollywood (A.M.), Bios Clinical Research, Palm Springs (P.S.), and Gilead Sciences, Foster City (S.C., R.E., P.W., R.S., L.B.B., C.C.C., M.D., J.M.B.) - all in California; Central Texas Clinical Research, Austin (C. Brinson), and Crofoot MD Clinic and Research Center, Houston (G.C.) - both in Texas; the Department of Infectious Diseases, Louisiana State University Health Sciences Center-New Orleans, New Orleans (M.C.); Howard Brown Health (C.C.) and the Division of Infectious Diseases, University of Illinois Health Sciences (R.M.N.) - both in Chicago; the Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami (S.D.-L.), Therafirst Medical Center, Fort Lauderdale (A.L.), Midway Immunology and Research Center, Fort Pierce (M.R.), and CAN Community Health, Sarasota (T.S.) - all in Florida; the Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN (A.G.); Washington Health Institute, Washington, DC (T.H.); Fenway Health Medical Clinic, Boston (K.H.M.); Philadelphia FIGHT Community Health Centers-Jonathan Lax Treatment Center, Philadelphia (K.M.); the Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham (O.T.V.G.); the Section of Infectious Diseases, Yale School of Medicine, New Haven, CT (O.O.); Centro Ararat, San Juan, Puerto Rico (M.A.-Q.); the HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Center and Center of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University (A.A.), and the Institute of HIV Research and Innovation-Pribta Tangerine Clinic (N.P.) - both in Bangkok; Complexo Hospitalar Universitário Professor Edgard Santos, Salvador (C. Brites), Universidade Federal de São Paulo (R.S.D.), Centro de Referência e Treinamento DST/AIDS-SP (J.V.M.), and Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (R.V.), São Paulo, Fundação Oswaldo Cruz-Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro (B.G.), Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus (M.L.), and the Infectious Diseases Service, Hospital Nossa Senhora da Conceição, Porto Alegre (B.S.) - all in Brazil; Fundación Huésped (P.C.) and Hospital General de Agudos José María Ramos Mejía (M.H.L.) - both in Buenos Aires; Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales, Universidad Nacional Mayor de San Marcos (J.A.G.-C., J.S.) and Via Libre (J.G.V.), Lima, and Asociación Civil Selva Amazónica, Iquitos (J.C.H.) - all in Peru; Desmond Tutu Health Foundation, Cape Town (R.K.), Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, School of Public Health, University of the Witwatersrand, Johannesburg (N.N.), and the Aurum Institute-Pretoria Clinical Research Site, Pretoria (Z.Z.) - all in South Africa; Centro de Investigacion Farmaceutica Especializada de Occidente, Guadalajara, Mexico (A.P.R.); and Gilead Sciences, Cambridge, United Kingdom (C.D.).
Background: Twice-yearly subcutaneous lenacapavir has been shown to be efficacious for prevention of HIV infection in cisgender women. The efficacy of lenacapavir for preexposure prophylaxis (PrEP) in cisgender men, transgender women, transgender men, and gender-nonbinary persons is unclear.
Methods: In this phase 3, double-blind, randomized, active-controlled trial, we randomly assigned participants in a 2:1 ratio to receive subcutaneous lenacapavir every 26 weeks or daily oral emtricitabine-tenofovir disoproxil fumarate (F/TDF).
Multiple Lax integrable higher dimensional AKNS(-1) equations and sine-Gordon equations.
Chaos
October 2024
School of Information Engineering, Zhejiang Ocean University, Zhoushan 316022, China.
Through the modified deformation algorithm related to conservation laws, the (1+1)-dimensional AKNS(-1) equations are extended to a (4+1)-dimensional AKNS(-1) system. When one, two, or three of the independent variables are removed, the (4+1)-dimensional AKNS(-1) system degenerates to some novel (3+1)-dimensional, (2+1)-dimensional, and (1+1)-dimensional AKNS(-1) systems, respectively. Under a simple dependent transformation, the (1+1)-dimensional AKNS(-1) equations turn into the classical sine-Gordon equation.
View Article and Find Full Text PDFResults and lessons learnt from the WISTERIA phase I trial combining AZD1775 with cisplatin pre- or post-operatively in head and neck cancer.
BJC Rep
January 2024
InHANSE, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
Background: Pre-clinical studies suggest AZD1775, a WEE1 kinase inhibitor, potentiates the activity of various chemotherapeutic agents.
Methods: WISTERIA was a prospective, parallel two-group, open-label, dose-finding, phase I clinical trial. Eligible patients had histologically confirmed oral, laryngeal, or hypopharyngeal squamous cell carcinoma, ECOG performance status 0/1, and aged ≥18-to-≤70 years.
Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.
Lancet Rheumatol
June 2024
Cancer Research UK Clinical Trials Unit, University of Birmingham, Edgbaston, Birmingham, UK; National Institute for Health Research, Birmingham Biomedical Research Centre, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. Electronic address:
Background: The humoral and T-cell responses to booster COVID-19 vaccine types in multidisease immunocompromised individuals who do not generate adequate antibody responses to two COVID-19 vaccine doses, is not fully understood. The OCTAVE DUO trial aimed to determine the value of third vaccinations in a wide range of patients with primary and secondary immunodeficiencies.
Methods: OCTAVE-DUO was a prospective, open-label, multicentre, randomised, controlled, phase 3 trial investigating humoral and T-cell responses in patients who are immunocompromised following a third vaccine dose with BNT162b2 or mRNA-1273, and of NVX-CoV2373 for those with lymphoid malignancies.
Advancing data honesty in experimental biology.
J Exp Biol
May 2024
The Shmunis School of Biomedicine and Cancer Research, Faculty of Life Sciences, Tel Aviv University, Tel Aviv 6997801, Israel.
The ease with which scientific data, particularly certain types of raw data in experimental biology, can be fabricated without trace begs urgent attention. This is thought to be a widespread problem across the academic world, where published results are the major currency, incentivizing publication of (usually positive) results at the cost of lax scientific rigor and even fraudulent data. Although solutions to improve data sharing and methodological transparency are increasingly being implemented, the inability to detect dishonesty within raw data remains an inherent flaw in the way in which we judge research.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!